MALLINCKRODT INC /MO

Mallinckrodt Inc. continues to serve as a specialty pharmaceutical manufacturer, developing and supplying branded and generic medicines that address critical care, autoimmune, and rare disease segments; its portfolio spans sophisticated biologics to hospital-centric therapeutics, keeping it aligned with SIC codes around 2834 for pharmaceutical preparations, even as the exact industry label remains unspecified. The company pursues hospitals, specialty pharmacies, and government healthcare programs that require reliable access to opioid antagonists, immunology treatments, and in-hospital analgesics, while continuing to adapt to evolving demand for sterile injectables and longer-duration pain management options. With regulatory oversight from FDA and other global authorities intensifying and the health sector under microscope for pricing, supply chain stability, and compliance with controlled-substance laws, Mallinckrodt faces material risks tied to litigation, reimbursement pressures, and extensive manufacturing standards; the latest filing is currently unknown. Track operational transparency by viewing live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025